The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Open accessAbstract
BACKGROUND: mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies. METHODS: -mutated cancer. Secondary end points included overall response and safety. RESULTS: -mutated cancer was greater with alpelisib-fulvestrant than with placebo-fulvestrant (26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 35.7% and 16.2%, respectively. In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%). Diarrhea of grade 3 occurred in 6.7% of patients in the alpelisib-fulvestrant group, as compared with 0.3% of those in the placebo-fulvestrant group; no diarrhea of grade 4 was reported. The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively. CONCLUSIONS: -mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only 20 patients (6%) in SOLAR-1 had been previously exposed to a CDK4/6 inhibitor.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the use of which as a single-agent is now suboptimal in the second line”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperglycemia occurs early during therapy (median time of onset of about 2 weeks from initiation of alpelisib) with an incidence of $60% overall and typically resolves upon treatment cessation (220-222).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [220]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PIK3CA-mutated cohort, alpelisib provided a PFS benefit of 11.0 months versus 5.7 months [hazard ratio (HR) for progression or death: 0.65; 95% confidence interval (CI) 0.50-0.85, P < 0.001].”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Toxicity was substantially increased in the alpelisib arm, especially hyperglycaemia, rash, gastrointestinal (GI) complaints (nausea, vomiting, loss of appetite, mucositis, diarrhoea) and fatigue, which lead to dose reductions/interruptions in around 70% of patients and discontinuations in 25%.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J. C. S., Bhattacharyya, G. S., Biganzoli, L., Cardoso, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,046
Self-citationUS Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,572
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Lopez, B. A., Barrios, C. H., Bergh, J. C. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,194
Self-citationO’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 657
Self-citationRugo, H. S., Rumble, R. B., Macrae, E. R., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L. J., Fowble, B. F., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 640
Self-citationConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationMiller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555
Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 538
Self-citationFritsch, C. M., Huang, A., Chatenay‐Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D. A., Erdmann, D., Pover, A. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 504
Flagged first, then by citations
1 of the 25 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol 2018 December 13 (Epub ahead of print).30543347
- Juric D Ciruelos E Rubovszky G et al. Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial. Presented at the San Antonio Breast Cancer Symposium San Antonio TX December 4–8 2018. abstract.
Cited by
Sorted by citations
Items 701–800 of 1,004
Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes
DiNome, M. L., Orozco, J. I. J., Matsuba, C., Manughian-Peter, A. O., Ensenyat-Méndez, M., Chang, S., Jalas, J. R., Salomon, M. P., & Marzese, D. M. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07565-8 · Cited by 24
Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer
Kutasovic, J. R., Reed, A. E. M., Sokolova, A., Lakhani, S. R., & Simpson, P. T. (2020) · Cancers · doi:10.3390/cancers12040848 · Cited by 24
Gagan, G., Lee, D. C., Guye, M. L., Sciver, R. E. V., Lee, P., Lafever, A., Anthony, P., Tang-Tan Angela, M., Winston, J. S., Şamli, B., et al. (2020) · Annals of Breast Cancer and Therapy · doi:10.36959/739/525 · Cited by 23
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer
Agostinetto, E., Debien, V., Marta, G. N., Lambertini, M., Piccart, M. J., & de Azambuja, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13535 · Cited by 24
Impact of Molecular Profiling on Therapy Management in Breast Cancer
Ultimescu, F., Hudiță, A., Popa, D. E., Olincă, M., Muresean, H. A., Ceaușu, M. C., Stanciu, D. I., Ginghină, O., & Gălățeanu, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13174995 · Cited by 25
Kim, E. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5758 · Cited by 31
Liquid biopsy in breast cancer: Redefining precision medicine
Schiavone, M. L., Scarpitta, R., Ravera, F., Bleve, S., Reduzzi, C., Cocco, F., Dameri, M., Zoppoli, G. M., Naccarato, A. G., Nuzzo, P. V., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100312 · Cited by 22
Huang, R. S. P., Li, X., Haberberger, J., Sokol, E. S., Severson, E. A., Duncan, D. L., Hemmerich, A. C., Edgerly, C. I., Williams, E. A., Elvin, J. A., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0449 · Cited by 22
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Mateo, L., Duran‐Frigola, M., Gris‐Oliver, A., Palafox, M., Scaltriti, M., Razavi, P., Chandarlapaty, S., Arribas, J., Bellet, M., Serra, V., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00774-x · Cited by 22
Spangle, J. M., Von, T., Pavlick, D. C., Khotimsky, A., Zhao, J. J., & Roberts, T. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000060117 · Cited by 22
Diabetic Ketoacidosis Associated With Alpelisib Treatment Of Metastatic Breast Cancer
Farah, S., Masri, N., Ghanem, H., & Azar, M. (2020) · AACE Clinical Case Reports · doi:10.4158/accr-2020-0452 · Cited by 22
Yip, H. Y. K., Chee, A., Ang, C., Shin, S., Ooms, L. M., Mohammadi, Z., Phillips, W. A., Daly, R. J., Cole, T. J., Bronson, R. T., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.027 · Cited by 23
Use of Liquid Biopsy to Detect PIK3CA Mutation in Metastatic Breast Cancer
Nakai, M., Yamada, T., Sekiya, K., Sato, A., Hankyo, M., Kuriyama, S., Takahashi, G., Kurita, T., Yanagihara, K., Yoshida, H., et al. (2021) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2022_89-107 · Cited by 22
Näsman, A., Holzhauser, S., Kostopoulou, O. N., Zupancic, M., Ährlund‐Richter, A., Du, J., & Dalianis, T. (2021) · Viruses · doi:10.3390/v13050910 · Cited by 22
Green, M. F., Bell, J. L., Hubbard, C. B., McCall, S. J., McKinney, M. S., Riedel, J., Menendez, C. S., Abbruzzese, J. L., Strickler, J. H., & Datto, M. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00030 · Cited by 24
Scheiter, A., Evert, K., Reibenspies, L. E., Cigliano, A., Annweiler, K., Müller, K., Pöhmerer, L., Xu, H., Cui, G., Itzel, T., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13135 · Cited by 23
Elfgen, C., & Bjelic‐Radisic, V. (2021) · Cancers · doi:10.3390/cancers13235994 · Cited by 23
Cani, A. K., Dolce, E. M., Darga, E. P., Hu, K. S., Liu, C., Pierce, J., Bradbury, K., Kilgour, E., Aung, K., Schiavon, G., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13150 · Cited by 21
Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors
Heynen, G. J. J. E., Lisek, K., Vogel, R., Wulf-Goldenberg, A., Alcaniz, J., Montaudon, É., Marangoni, E., & Birchmeier, W. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01521-3 · Cited by 23
Poh, J., Ngeow, K. C., Pek, M., Tan, K.-H., Lim, J. S., Chen, H., Ong, C. K., Lim, J. S., Lim, S. T., Lim, C. M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267389 · Cited by 22
Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future
Huang, W., Hao, Z., Mao, F., & Guo, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.911876 · Cited by 23
Rubovszky, G., Kocsis, J., Boér, K., Chilingirova, N. P., Dank, M., Kahán, Z., Kaidarova, D., Kövér, E., Vertáková-Krakovská, B., Máhr, K., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610383 · Cited by 22
Self-citationCell-free DNA as a biomarker in cancer
Eibl, R. H., & Schneemann, M. (2022) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2022.20 · Cited by 22
Roufai, D. B., Gonçalvès, A., Rouge, T. D. L. M., Akla, S., Blonz, C., Grenier, J., Gligorov, J., Saghatchian, M., Bailleux, C., Simon, H., et al. (2023) · Oncogene · doi:10.1038/s41388-022-02585-3 · Cited by 22
Altena, R., Tzortzakakis, A., af Burén, S., Tran, T. A., Frejd, F. Y., Bergh, J. C. S., & Axelsson, R. (2023) · EJNMMI Research · doi:10.1186/s13550-023-00995-2 · Cited by 24
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 24
Cescon, D. W., Hilton, J. F., Morales, S. M., Layman, R. M., Pluard, T., Yeo, B. J., Park, I. H., Provencher, L., Kim, S., Im, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0133 · Cited by 22
Yip, H. Y. K., Shin, S., Chee, A., Ang, C., Rossello, F. J., Wong, L. H., Nguyen, L. K., & Papa, A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00496-y · Cited by 25
Bottosso, M., Mosele, F., Michiels, S., Cournède, P.-H., Doğan, S., Labaki, C., & André, F. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102247 · Cited by 23
Self-citationVasseur, A., Cabel, L., Hego, C., Taka, W., Trabelsi‐Grati, O., Renouf, B., Lerebours, F., Loirat, D., Brain, E. G. C., Cottu, P. H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02986-6 · Cited by 24
Sánchez-Bayona, R., de, A. L., Gilarranz, Y. J., de Torre, A. S., Alva, M., Echavarría, I., Moreno, F., Tolosa, P., López, B. H., de Luna, A., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07324-8 · Cited by 24
Self-citationLuu, M., Vabres, P., Devilliers, H., Loffroy, R., Phan, A., Martin, L., Morice‐Picard, F., Petit, F., Willems, M., Bessis, D., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01290-y · Cited by 22
Bastos, I. F., Rebelo, S., & Silva, V. L. M. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111073 · Cited by 21
LIN28B-mediated PI3K/AKT pathway activation promotes metastasis in colorectal cancer models
Shin, A. E., Sugiura, K., Kariuki, S. W., Cohen, D. A., Flashner, S. P., Klein–Szanto, A. J., Nishiwaki, N., De, D., Vasan, N., Gabre, J. T., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186035 · Cited by 22
Su, Y., Zhu, W., Su, T., Huang, L., Qin, M., Wang, Q., Xu, Q., Li, Y., & Xiu, J. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03469-5 · Cited by 21
Hurvitz, S. A., Layman, R. M., Curigliano, G., André, F., Cristofanilli, M., Kim, S., Rodriguez, J. L. M., Nadal, J. C., Kim, G. M., Lo, L. L., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02643 · Cited by 25
Self-citationSchütz, F., Fasching, P. A., Welslau, M., Hartkopf, A. D., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1001-9925 · Cited by 21
Borazanci, E. H., Pishvaian, M. J., Nemunaitis, J. J., Weekes, C. D., Huang, J. C., & Rajakumaraswamy, N. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0321 · Cited by 21
Cardiovascular toxicity of PI3Kα inhibitors
Sadasivan, C., Zhabyeyev, P., Labib, D., White, J. A., Paterson, D. I., & Oudit, G. Y. (2020) · Clinical Science · doi:10.1042/cs20200302 · Cited by 22
A systematic review and meta-analysis of selected toxicity endpoints of alpelisib
Shields, M. D., Mo, Q., Armitage, M., Sharpe, S. C., & Costa, R. L. B. (2020) · Oncotarget · doi:10.18632/oncotarget.27770 · Cited by 21
Zhu, W., & Xu, B. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0795-4 · Cited by 21
Sun, Y., Fu, R., Lin, S., Zhang, J., Ji, M., Zhang, Y., Wu, D., Zhang, K., Tian, H., Zhang, M., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115890 · Cited by 21
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling
Gao, S. P., Kiliti, A. J., Zhang, K., Vasani, N. B., Mao, N., Jordan, E., Wise, H. C., Shrestha-Bhattarai, T., Hu, W., Dorso, M. A., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0623 · Cited by 21
Targetable alterations in invasive pleomorphic lobular carcinoma of the breast
Riedlinger, G., Joshi, S. S., Hirshfield, K. M., Barnard, N., & Ganesan, S. (2021) · Breast Cancer Research · doi:10.1186/s13058-020-01385-5 · Cited by 21
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations
Layman, R. M., & Arun, B. K. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000499 · Cited by 22
Cardiovascular toxicity of breast cancer treatment: an update
Papageorgiou, C., Andrikopoulou, Α., Dimopoulos, M. A., & Zagouri, F. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04254-w · Cited by 21
Cheung, Y.-M. M., McDonnell, M., & Hamnvik, O.-P. R. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100776 · Cited by 21
Patient-Centered Diabetes Care of Cancer Patients
Kotwal, A., Cheung, Y.-M. M., Cromwell, G. E., Drincic, A., Leblebjian, H., Quandt, Z., Rushakoff, R. J., & McDonnell, M. E. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01435-y · Cited by 23
Thill, M., Lüftner, D., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2022) · Breast Care · doi:10.1159/000524789 · Cited by 23
Self-citationTreating non-small cell lung cancer by targeting the PI3K signaling pathway
Jiang, L., Zhang, J., Xu, Y., Xu, H., & Wang, M. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002195 · Cited by 23
Xu, H., Wang, Y., Han, Y., Wu, Y., Wang, J., & Xu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956464 · Cited by 21
Choong, G. M. Y., Liddell, S. S., Ferre, R. A. L., O'Sullivan, C. C., Ruddy, K. J., Haddad, T. C., Hobday, T. J., Peethambaram, P. P., Liu, M., Goetz, M. P., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06713-1 · Cited by 22
Konstantinopoulos, P. A., González-Martı́n, A., Cruz, F. M., Friedlander, M. L., Glasspool, R. M., Lorusso, D., Marth, C., Monk, B. J., Kim, J., Hinson, P., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0666 · Cited by 21
Therapeutics targeting the metastatic breast cancer bone microenvironment
Ihle, C. L., Wright-Hobart, S., & Owens, P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108280 · Cited by 22
Nero, C., Duranti, S., Giacomini, F., Minucci, A., Giacò, L., Piermattei, A., Genuardi, M., Pasciuto, T., Urbani, A., Daniele, G., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101746 · Cited by 20
Mouabbi, J. A., Raghavendra, A. S., Bassett, R. L., Hassan, A. A., Tripathy, D., & Layman, R. M. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00499-7 · Cited by 21
Varella, L., & Cristofanilli, M. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s400563 · Cited by 22
Mai, N., Abuhadra, N. K., & Jhaveri, K. L. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.05.012 · Cited by 24
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
Yang, C., Brezden‐Masley, C., Joy, A. A., Sehdev, S. R., Modi, S., Simmons, C. E., & Henning, J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231175440 · Cited by 22
What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care
Anders, C. K., LeBoeuf, N. R., Bashoura, L., Faiz, S. A., Shariff, A. I., & Thomas, A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279465 · Cited by 21
Klinghammer, K. F., Politz, O., Eder, T., Otto, R., Raguse, J.-D., Albers, A. E., Kaufmann, A. M., Tinhofer, I., Hoffmann, J., Keller, U. B., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27763 · Cited by 21
Clinical implications of genomic alterations in metastatic prostate cancer
Sumiyoshi, T., Chi, K. N., & Wyatt, A. W. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00308-x · Cited by 21
A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer
Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 21
Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier
Curtaz, C. J., Kiesel, L., Meybohm, P., Wöckel, A., & Burek, M. (2022) · Cancers · doi:10.3390/cancers14205132 · Cited by 24
Mahmoud, M. E., Ahmed, E., Ragab, H. M., El‐Telbany, R. F. A., & Hassan, R. A. (2024) · RSC Advances · doi:10.1039/d4ra04036h · Cited by 20
Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies
Luong, H. T. T., Vercammen, S., de Marco, A., de Rooster, H., & Cosma, A. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1623327 · Cited by 22
Srijakotre, N., Liu, H.-J., Nobis, M., Man, J., Yip, H. Y. K., Papa, A., Abud, H. E., Anderson, K. I., Welch, H. C. E., Tiganis, T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006445117 · Cited by 20
Sultova, E., Westphalen, C. B., Jung, A., Kumbrink, J., Kirchner, T., Mayr, D. C., Rudelius, M., Ormanns, S., Heinemann, V., Metzeler, K. H., et al. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05881-z · Cited by 20
Huang, C., Tsai, Y., Liu, C., Chao, T., Lien, P., Lin, Y., Feng, C.-J., Chiu, J., Hsu, C., & Tseng, L. (2021) · BMC Cancer · doi:10.1186/s12885-021-07931-4 · Cited by 20
Leenhardt, F., Alexandre, M., & Jacot, W. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873952 · Cited by 21
Mishra, R., Yuan, L., Patel, H. M., Karve, A. S., Zhu, H., White, A., Alanazi, S., Desai, P. B., Merino, E. J., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042088 · Cited by 20
Im, Y., Karabulut, B., Lee, K. S., Park, B., Adhav, A. S., Çınkır, H. Y., Abdel‐Razeq, H., Chang, Y., Aksoy, S., Im, S., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06173-z · Cited by 20
Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor
Kim, S., Seung, B., Cho, S., Lim, H., Bae, M., & Sur, J. (2021) · Animals · doi:10.3390/ani11072079 · Cited by 20
Tan, A. C., Boggs, D. H., Lee, E. Q., Kim, M. M., Mehta, M. P., & Khasraw, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780379 · Cited by 22
Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer
Torregrosa, M. D., Barco, S. D., Cotes, A., Roso, L. L., Servitja, S., & Sarrió, R. G. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02766-8 · Cited by 22
Gu, Z., Shi, C., Li, J., Han, Y., Sun, B., Zhang, W., Wu, J., Zhou, G., Ye, W., Li, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02373-6 · Cited by 20
Douganiotis, G., Kesisis, G., Lalla, E., Korantzis, I., Boukovinas, I., & Papazisis, K. T. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10146 · Cited by 21
Sammons, S. L., Raskina, K., Danziger, N. A., Alder, L., Schrock, A. B., Venstrom, J. M., Knutson, K. L., Thompson, E. A., McGregor, K., Sokol, E. S., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00149 · Cited by 20
BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target
Bezrookove, V., Khan, I. A., Nosrati, M., Miller, J. R., McAllister, S. D., Dar, A. A., & Kashani–Sabet, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1011173 · Cited by 20
Irshaid, L., Costigan, D. C., Dong, F., Matulonis, U. A., Nucci, M. R., & Kolin, D. L. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100123 · Cited by 20
Zhang, X., Wang, Y., Zhang, X., Shen, Y., Yang, K., Ma, Q., Qiao, Y., Shi, J., Wang, Y., Xu, L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01359-x · Cited by 21
Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation
de Godoy, B. L. V., Moschetta‐Pinheiro, M. G., Chuffa, L. G. D. A., Ponde, N. F., Reiter, R. J., Colombo, J., & Zuccari, D. A. P. D. C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121708 · Cited by 20
Almeida, C. F., Teixeira, N. A. A., Valente, M. J., Vinggaard, A. M., Correia‐da‐Silva, G., & Amaral, C. (2023) · Cancers · doi:10.3390/cancers15092517 · Cited by 20
Clinical trial designs for evaluating and exploiting cancer evolution
Garces, A. I., Porta, N., Graham, T. A., & Banerji, U. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102583 · Cited by 19
A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm
Roy, A. M., Kumarasamy, V. M., Dhakal, A., O'Regan, R. M., & Gandhi, S. (2023) · Cancer · doi:10.1002/cncr.34904 · Cited by 21
Chen, H., Hu, X., Wang, D., Wang, Y., Yu, Y., & Yao, H. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101738 · Cited by 20
He, B., Bie, Q., Zhao, R., Yan, Y., Dong, G., Zhang, B., Wang, S., Xu, W., Tian, D., Hao, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101510 · Cited by 20
Shah, O. S., Nasrazadani, A., Foldi, J., Atkinson, J. M., Kleer, C. G., McAuliffe, P. F., Johnston, T. J., Stallaert, W., da Silva, E. M., Selenica, P., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322068121 · Cited by 21
Steger, G. G., Egle, D., Bartsch, R., Pfeiler, G., Petru, E., Greil, R., Helfgott, R., Marth, C., Öhler, L., Hubalek, M., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.01.035 · Cited by 20
Optimal Clinical Management and the Molecular Biology of Angiosarcomas
Chen, T. W., Burns, J., Jones, R. L., & Huang, P. H. (2020) · Cancers · doi:10.3390/cancers12113321 · Cited by 22
Updates on the treatment of invasive breast cancer: Quo Vadimus?
Nigdelis, M. P., Karamouzis, M. V., Kontos, M. C., Alexandrou, A. P., Goulis, D. G., & Lambrinoudaki, I. V. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.11.006 · Cited by 21
Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature
Carrillo, M., Rodriguez, R. M., Walsh, C. L., & McGarvey, M. E. (2021) · AACE Clinical Case Reports · doi:10.1016/j.aace.2020.11.028 · Cited by 20
Sun, C., Wang, S., Zhang, Y., Yang, F., Zeng, T., Meng, F., Yang, M., Yang, Y., Hua, Y., Fu, Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628677 · Cited by 20
Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach
Xi, J., Ma, C. X., & O’Shaughnessy, J. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00274 · Cited by 20
Major clinical research advances in gynecologic cancer in 2019
Kim, M., Suh, D. H., Lee, K.-H., Eom, K., Lee, J., Lee, Y.-Y., Hansen, H. F., Mirza, M. R., & Kim, J. (2020) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2020.31.e48 · Cited by 19
Akahane, T., Kanomata, N., Harada, O., Yamashita, T., Kurebayashi, J., Tanimoto, A., & Moriya, T. (2020) · BMC Cancer · doi:10.1186/s12885-020-07432-w · Cited by 19
Self-citationSun, B., Jiang, Y., Cui, H., Xia, F., Han, G., Dai, X., Zhou, S., Mao, H., & Wang, B. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02806-1 · Cited by 20
Keegan, N. M., Furney, S. J., Walshe, J. M., Gullo, G., Kennedy, M., Smith, D., McCaffrey, J., Kelly, C. M., Egan, K., Kerr, J., et al. (2021) · Cancers · doi:10.3390/cancers13061225 · Cited by 18
A review of the endocrine resistance in hormone-positive breast cancer.
Chien, T.-J. (2021) · PubMed · Cited by 22
Lu, Y., Yeo, W., Yap, Y. S., Park, Y. H., Tamura, K., Li, H., & Cheng, R. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00838-x · Cited by 20
Self-citation
Metadata
- Authors
- André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., & Juric, D.
- Affiliations
- Université Paris-Sud (FR)
- From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l’Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) — all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt — both in Germany (S.L.); UCSF Helen Diller Family Comprehensive...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-16
- Volume
- 380
- Issue
- 20
- Pages
- 1929-1940
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945564879
- Cited by
- 2,622
- References
- 25
- Citations by year
- 2026: 314 · 2025: 356 · 2024: 370 · 2023: 329 · 2022: 375 · 2021: 450 · 2020: 345 · 2019: 81
- FWCI
- 231.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Hispana (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- alpelisib, PIK3CA mutation, hormone receptor-positive breast cancer, HER2-negative breast cancer, advanced breast cancer, PI3Kα inhibitor, fulvestrant, endocrine therapy, hyperglycemia, diarrhea, adverse events
- MeSH terms
- Fulvestrant, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diarrhea, Female, Humans, Middle Aged, Mutation, Receptors, Estrogen, Receptors, Progesterone, Thiazoles, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Hormonal, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
